Cancer Antigen (CA) 125 in the Presence of Human Antimouse Antibodies (HAMA)
Also known as: CA-125 in the Presence of HAMA
Use
Eliminate interference from HAMA in the CA 125 assay to help monitor disease progression in nonmucinous epithelial neoplasms of the ovary. This test is performed in the same way as the Cancer Antigen (CA) 125 test except that the interference from HAMA present in the specimen is eliminated by use of a blocking reagent.
Special Instructions
A blocking agent is used to remove interference from HAMA in the CA 125 assay. Patients should be asked about biotin supplementation, as high doses can interfere with the test; discontinue biotin at least 72 hours prior to sample collection.
Limitations
The CA 125 test is not specific to ovarian tumors and cannot differentiate between benign and malignant tumors. It is not a screening test for cancer.
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 10334-1
- 10334-1
Result Turnaround Time
4-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Red-top tube or gel-barrier tube
Collection Instructions
If a red-top tube is used, transfer separated serum to a plastic transport tube.
Patient Preparation
It is suggested that the assay not be performed until at least three weeks after the completion of primary chemotherapy and at least two months following abdominal surgery.
Storage Instructions
Room temperature; stable at room temperature or refrigerated for 14 days.
Causes for Rejection
Citrate plasma specimen; improper labeling